No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades

Br J Haematol. 2021 Aug;194(3):635-638. doi: 10.1111/bjh.17488. Epub 2021 Apr 29.

Thomas Chalopin¹, Nicolas Vallet¹, Olivier Theisen², Marlène Ochmann³, Mourad Tiab⁴, Pascal Godmer⁵, Carole Barin⁶, Olivier Hérault^{7

8}, Emmanuel Gyan^{1

8}, Steven Le Gouill^{9

10

11}, Hervé Avet-Loiseau¹², Lotfi Benboubker¹, Philippe Moreau^{9

10

11}, Cyrille Touzeau^{9

10

11}

¹ Department of Hematology and Cell Therapy, Tours University Hospital, Tours, France.
² Hematology Biology, Nantes University Hospital, Nantes, France.
³ Department of Hematology, Orleans Regional Hospital, Orleans, France.
⁴ Department of Hematology, La Roche-Sur-Yon Hospital, La Roche-Sur-Yon, France.
⁵ Department of Hematology, Vannes Hospital, Vannes, France.
⁶ Department of Cytogenetics, University Hospital of Tours, France.
⁷ Department of Biological Hematology, University Hospital of Tours, France.
⁸ CNRS ERL 7001 LNOx, University of Tours, Tours, France.
⁹ Department of Hematology, University Hospital, Nantes, France.
¹⁰ CRCNA, INSERM, CNRS, University of Nantes, Nantes, France.
¹¹ Site de Recherche Intégrée sur le Cancer (SIRIC) «ILIAD», Nantes, France.
¹² IUC Oncopole, Toulouse, CRCT, Toulouse, France.

No abstract available

Publication types